CA9 and metastatic malignant neoplasm in the lymph nodes: Given the established role of CAIX as a promising biomarker of metastatic progression 105, our group developed a CAIX-targeted probe (CAIX-800) and investigated its targeting efficiency in preclinical models, revealing its superior capability to capture clinically undetectable lymph node metastases (< 5 mm) 106.